Daniel J DeAngelo (Daniel DeAngelo)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 81

Top Venues

Leukemia

Blood advances

Blood cancer journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Dana-Farber Cancer Institute

Albert Einstein College of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Dana-Farber Cancer Institute Jul 01 1999

United States

Chief of the Division of Leukemia :: Medical Oncology

Education History

Albert Einstein College of Medicine

United States

PHD :: Molecular Genetics (Geoffrey Childs, PhD)

Yeshiva University Albert Einstein College of Medicine

United States

MSC :: Biology (Division of Medical Sciences)

University of California

United States

BSC

Publications

Jorge E Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro, Andreas Hochhaus, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael W Deininger, Yeow Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Rea
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38 (7) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia (2024)
Jan Philipp Bewersdorf, Shai Shimony, Rory Michael Shallis, Yiwen Liu, Guillaume Berton, Eva Johanna Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, Rebecca Bystrom, R Coleman Lindsley, Evan C Chen, Jorge Miguel Ramos Perez, Anthony S Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Sylvain Garciaz, Brian J Ball, Maximilian Stahl
Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML. Blood advances (2024)
Jorge E Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro, Andreas Hochhaus, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael W Deininger, Yeow Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Rea
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38 (7) (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 38 (4) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia (2024)
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, Michela Ansuinelli, Jennifer Brock, Corey S Cutler, Mahasweta Gooptu, Vincent T Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Roman Shapiro, Daniel J DeAngelo, Richard M Stone, Denbaa Bat-Erdene, Jeremy Adam Ryan, Manuel E Contreras, Geoffrey G Fell, Anthony Letai, Jerome Ritz, R Coleman Lindsley, Robert J Soiffer, Joseph H Antin
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood advances 8 (4) (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia (2024)
Yaqi Zhao, A Douglas Laird, Kathryn G Roberts, Rolla Yafawi, Hagop Kantarjian, Daniel J DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan M O'Brien, Elias Jabbour, Ryan D Cassaday, Melanie R Loyd, Scott Olsen, Geoffrey A Neale, Xueli Liu, Erik Vandendries, Anjali S Advani, Charles G Mullighan
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood advances 8 (12) (2024)
Rathnam K Venkat, Robert A Redd, Amyah C Harris, Martin J Aryee, Anna E Marneth, Baransel Kamaz, Chulwoo J Kim, Mohammed Wazir, Lachelle Dawn Weeks, Maximilian Stahl, Daniel J DeAngelo, R Coleman Lindsley, Marlise R Luskin, Gabriela S Hobbs, Joan How
Risk of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis. Blood advances (2024)
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, Michela Ansuinelli, Jennifer Brock, Corey S Cutler, Mahasweta Gooptu, Vincent T Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Roman Shapiro, Daniel J DeAngelo, Richard M Stone, Denbaa Bat-Erdene, Jeremy Adam Ryan, Manuel E Contreras, Geoffrey G Fell, Anthony Letai, Jerome Ritz, R Coleman Lindsley, Robert J Soiffer, Joseph H Antin
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood advances 8 (4) (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 38 (3) (2024)
Yaqi Zhao, A Douglas Laird, Kathryn G Roberts, Rolla Yafawi, Hagop Kantarjian, Daniel J DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan M O'Brien, Elias Jabbour, Ryan D Cassaday, Melanie R Loyd, Scott Olsen, Geoffrey A Neale, Xueli Liu, Erik Vandendries, Anjali S Advani, Charles G Mullighan
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood advances 8 (12) (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38 (7) (2024)
Jorge E Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro, Andreas Hochhaus, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael W Deininger, Yeow Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Rea
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38 (7) (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38 (7) (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38 (7) (2024)
Johann-Christoph Jann, Christopher B Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun, Anne Charles, Kevin M Copson, Shougat Barua, Manja Meggendorfer, Niroshan Nadarajah, Shai Shimony, Eric S Winer, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Jacqueline S Garcia, Torsten Haferlach, R Coleman Lindsley, Marlise R Luskin, Maximilian Stahl, Zuzana Tothova
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia 38 (9) (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 38 (3) (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 38 (3) (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 38 (4) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Yaqi Zhao, A Douglas Laird, Kathryn G Roberts, Rolla Yafawi, Hagop Kantarjian, Daniel J DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan M O'Brien, Elias Jabbour, Ryan D Cassaday, Melanie R Loyd, Scott Olsen, Geoffrey A Neale, Xueli Liu, Erik Vandendries, Anjali S Advani, Charles G Mullighan
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood advances 8 (12) (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 38 (4) (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38 (7) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 38 (3) (2024)
Yaqi Zhao, A Douglas Laird, Kathryn G Roberts, Rolla L Yafawi, Hagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan M O'Brien, Elias J Jabbour, Ryan D Cassaday, Melanie R Loyd, Scott R Olsen, Geoffrey A Neale, Xueli Liu, Erik Vandendries, Anjali S Advani, Charles G Mullighan
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood advances (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, Michela Ansuinelli, Jennifer Brock, Corey S Cutler, Mahasweta Gooptu, Vincent T Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Roman Shapiro, Daniel J DeAngelo, Richard M Stone, Denbaa Bat-Erdene, Jeremy Adam Ryan, Manuel E Contreras, Geoffrey G Fell, Anthony Letai, Jerome Ritz, R Coleman Lindsley, Robert J Soiffer, Joseph H Antin
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood advances 8 (4) (2024)
Jorge E Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro, Andreas Hochhaus, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael W Deininger, Yeow Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Rea
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 38 (3) (2024)
Johann-Christoph Jann, Christopher B Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun, Anne Charles, Kevin M Copson, Shougat Barua, Manja Meggendorfer, Niroshan Nadarajah, Shai Shimony, Eric S Winer, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Jacqueline S Garcia, Torsten Haferlach, R Coleman Lindsley, Marlise R Luskin, Maximilian Stahl, Zuzana Tothova
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia 38 (9) (2024)
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, Michela Ansuinelli, Jennifer Brock, Corey S Cutler, Mahasweta Gooptu, Vincent T Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Roman M Shapiro, Daniel J DeAngelo, Richard M Stone, Denbaa Bat-Erdene, Jeremy Adam Ryan, Manuel E Contreras, Geoffrey G Fell, Anthony Letai, Jerome Ritz, R Coleman Lindsley, Robert J Soiffer, Joseph H Antin
Prophylactic maintenance with venetoclax/azacitidine after reduced intensity conditioning allo-transplant for high risk MDS and AML. Blood advances (2024)
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, Michela Ansuinelli, Jennifer Brock, Corey S Cutler, Mahasweta Gooptu, Vincent T Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Roman Shapiro, Daniel J DeAngelo, Richard M Stone, Denbaa Bat-Erdene, Jeremy Adam Ryan, Manuel E Contreras, Geoffrey G Fell, Anthony Letai, Jerome Ritz, R Coleman Lindsley, Robert J Soiffer, Joseph H Antin
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood advances 8 (4) (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38 (7) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Jorge E Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro, Andreas Hochhaus, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael W Deininger, Yeow Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Rea
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38 (7) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia (2024)
Johann-Christoph Jann, Christopher B Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun, Anne Charles, Kevin M Copson, Shougat Barua, Manja Meggendorfer, Niroshan Nadarajah, Shai Shimony, Eric S Winer, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Jacqueline S Garcia, Torsten Haferlach, R Coleman Lindsley, Marlise R Luskin, Maximilian Stahl, Zuzana Tothova
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia 38 (9) (2024)
Johann-Christoph Jann, Christopher B Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun, Anne Charles, Kevin M Copson, Shougat Barua, Manja Meggendorfer, Niroshan Nadarajah, Shai Shimony, Eric S Winer, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Jacqueline S Garcia, Torsten Haferlach, R Coleman Lindsley, Marlise R Luskin, Maximilian Stahl, Zuzana Tothova
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia (2024)
Yaqi Zhao, A Douglas Laird, Kathryn G Roberts, Rolla Yafawi, Hagop Kantarjian, Daniel J DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan M O'Brien, Elias Jabbour, Ryan D Cassaday, Melanie R Loyd, Scott Olsen, Geoffrey A Neale, Xueli Liu, Erik Vandendries, Anjali S Advani, Charles G Mullighan
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood advances 8 (12) (2024)
Evan C Chen, Helen Gandler, Isidora Tošić, Geoffrey G Fell, Ashlee Fiore, Olga Pozdnyakova, Daniel J DeAngelo, Ilene Galinsky, Marlise R Luskin, Martha S Wadleigh, Eric S Winer, Rebecca Leonard, Kelsey O'Day, Adrienne de Jonge, Donna S Neuberg, A Thomas Look, Richard M Stone, David A Frank, Jacqueline S Garcia
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (5) (2023)
Shai Shimony, Yael Flamand, Yannis K Valtis, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Richard M Stone, Martha Wadleigh, Donna S Neuberg, Daniel J DeAngelo, Marlise R Luskin
Effect of BMI on Toxicities and Survival Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials. Blood advances (2023)
Glenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, Fabricio Racca, Doris V Quon, Serge Leyvraz, Dagmar Hess, Bhumsuk Keam, Jordi Rodon Ahnert, Myung-Ju Ahn, Hye Ryun Kim, Andreas Schneeweiß, Josep-María Ribera, Daniel J DeAngelo, Jose Manuel Perez Garcia, Javier Cortes, Oliver Schönborn-Kellenberger, Dirk Weber, Pavel Pisa, Michael Bauer, Laura Beni, Maria Bobadilla, Raj Lehal, Michele Vigolo, Florian D Vogl, Elena Garralda
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Cancer research communications 3 (9) (2023)
Andrew Hantel, Colin Cernik, Hajime Uno, Thomas P Walsh, Gregory Sampang Calip, Daniel J DeAngelo, Christopher S Lathan, Gregory A Abel
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Andrew Hantel, Colin Cernik, Hajime Uno, Thomas P Walsh, Gregory Sampang Calip, Daniel J DeAngelo, Christopher S Lathan, Gregory A Abel
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Evan C Chen, Helen Gandler, Isidora Tošić, Geoffrey G Fell, Ashlee Fiore, Olga Pozdnyakova, Daniel J DeAngelo, Ilene Galinsky, Marlise R Luskin, Martha S Wadleigh, Eric S Winer, Rebecca Leonard, Kelsey O'Day, Adrienne de Jonge, Donna S Neuberg, A Thomas Look, Richard M Stone, David A Frank, Jacqueline S Garcia
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (5) (2023)
Evan C Chen, Helen Gandler, Isidora Tošić, Geoffrey G Fell, Ashlee Fiore, Olga Pozdnyakova, Daniel J DeAngelo, Ilene Galinsky, Marlise R Luskin, Martha S Wadleigh, Eric S Winer, Rebecca Leonard, Kelsey O'Day, Adrienne de Jonge, Donna S Neuberg, A Thomas Look, Richard M Stone, David A Frank, Jacqueline S Garcia
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (5) (2023)
Andrew Hantel, Colin Cernik, Hajime Uno, Thomas P Walsh, Gregory Sampang Calip, Daniel J DeAngelo, Christopher S Lathan, Gregory A Abel
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Andrew Hantel, Colin Cernik, Hajime Uno, Thomas P Walsh, Gregory Sampang Calip, Daniel J DeAngelo, Christopher S Lathan, Gregory A Abel
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Andrew A Lane, Jacqueline S Garcia, Evangeline G Raulston, Jada Lauren N Garzon, Ilene Galinsky, Emilie W Baxter, Rebecca Leonard, Daniel J DeAngelo, Marlise R Luskin, Christopher R Reilly, Maximilian Stahl, Richard M Stone, Rahul S Vedula, Martha Wadleigh, Eric S Winer, Tariq I Mughal, Christopher Brooks, Ira V Gupta, Kristen E Stevenson, Donna S Neuberg, Siyang Ren, Julia H Keating, Marina Y Konopleva, Anthony S Stein, Naveen Pemmaraju
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood advances (2023)
Andrew Hantel, Colin Cernik, Hajime Uno, Thomas P Walsh, Gregory Sampang Calip, Daniel J DeAngelo, Christopher S Lathan, Gregory A Abel
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Shai Shimony, Daniel J DeAngelo, Marlise R Luskin
Nelarabine: When, Where and How to Use it When Treating T-cell Acute Lymphoblastic Leukemia. Blood advances (2023)
Andrew Hantel, Colin Cernik, Hajime Uno, Thomas P Walsh, Gregory Sampang Calip, Daniel J DeAngelo, Christopher S Lathan, Gregory A Abel
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Michael J Mauro, Timothy P Hughes, Dong-Wook Kim, Delphine Rea, Jorge E Cortes, Andreas Hochhaus, Koiji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver Ottmann, Hironobu Minami, Yeow Tee Goh, Daniel J DeAngelo, Michael C Heinrich, Valle Gómez-García de Soria, Philipp le Coutre, Francois-Xavier Mahon, Jeroen J W M Janssen, Michael Deininger, Naranie Shanmuganathan, Mark Blaine Geyer, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Matthias Hoch, Fabian Lang
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia (2023)
Jurjen Versluis, Manu Pandey, Yael Flamand, J Erika Haydu, Roger Belizaire, Mark G Faber, Rahul S Vedula, Anne Charles, Kevin M Copson, Shai Shimony, Alon Rozental, Pavan K Bendapudi, Ofir Wolach, Elizabeth A Griffiths, James E Thompson, Richard M Stone, Daniel J DeAngelo, Donna Neuberg, Marlise R Luskin, Eunice S Wang, R Coleman Lindsley
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. Blood advances 6 (9) (2022)
Evan C Chen, Helen Gandler, Isidora Tošić, Geoffrey G Fell, Ashlee Fiore, Olga Pozdnyakova, Daniel J DeAngelo, Ilene Galinsky, Marlise R Luskin, Martha S Wadleigh, Eric S Winer, Rebecca Leonard, Kelsey O'Day, Adrienne de Jonge, Donna S Neuberg, A Thomas Look, Richard M Stone, David A Frank, Jacqueline S Garcia
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Jason Gotlib, Andreas Reiter, Daniel J DeAngelo
Avapritinib for advanced systemic mastocytosis. Blood 140 (15) (2022)
Jacqueline S Garcia, Yael Flamand, Livius Penter, Michael Keng, Benjamin Tomlinson, Lourdes M Mendez, Paul B Koller, Nicole Cullen, Yohei Arihara, Kathleen Lindahl Pfaff, Jacquelyn O Wolff, Andrew M Brunner, Ilene Galinsky, Asad Bashey, Joseph H Antin, Corey S Cutler, Vincent T Ho, Brian A Jonas, Marlise R Luskin, Martha Wadleigh, Eric S Winer, Alexandra Savell, Rebecca Leonard, Taylor Robertson, Matthew S Davids, Howard Streicher, Scott J Rodig, Jerome Ritz, Catherine J Wu, Daniel J DeAngelo, Donna Neuberg, Richard M Stone, Robert J Soiffer
Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Blood (2022)
Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti H Radia, Johannes Lübke, Priyanka J Bobbili, Aolin Wang, Chelsea Norregaard, Saša Dimitrijevic, Erin Sullivan, Melinda Louie-Gao, Juliana Schwaab, Ilene A Galinsky, Cecelia Perkins, Wolfgang R Sperr, Priya Sriskandarajah, Andi Chin, Selvam R Sendhil, Mei Sheng Duh, Peter Valent, Daniel J DeAngelo
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia 36 (8) (2022)
Andreas Reiter, Juliana Schwaab, Daniel J DeAngelo, Jason Gotlib, Michael W Deininger, Kristen M Pettit, Iván Alvarez-Twose, Alessandro Maria Maria Vannucchi, Jens Peter Panse, Uwe Platzbecker, Olivier Hermine, Ingunn Dybedal, Hui-Min Lin, Svetlana N Rylova, Katrin Ehlert, Saša Dimitrijević, Deepti H Radia
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood advances 6 (21) (2022)
Blandine Roux, Camille Vaganay, Jesse D Vargas, Gabriela Alexe, Chaima Benaksas, Bryann Pardieu, Nina Fenouille, Jana M Ellegast, Edyta Malolepsza, Frank Ling, Gaetano Sodaro, Linda Ross, Yana Pikman, Amy Saur Conway, Yangzhong Tang, Tony Wu, Daniel J Anderson, Ronan Le Moigne, Han-Jie Zhou, Frédéric Luciano, Christina R Hartigan, Ilene Galinsky, Daniel J DeAngelo, Richard M Stone, Patrick Auberger, Monica Schenone, Steven A Carr, Josée Guirouilh-Barbat, Bernard S Lopez, Mehdi Khaled, Kasper Lage, Olivier Hermine, Michael T Hemann, Alexandre Puissant, Kimberly Stegmaier, Lina Benajiba
Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Science translational medicine 13 (587) (2021)
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, Corey S Cutler, Jennifer Brock, Mahasweta Gooptu, Vincent T Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Roman M Shapiro, Fiona Loschi, Jeremy Adam Ryan, Geoffrey Fell, Hannah Q Karp, Jennifer A Woyach, Annette S Kim, Danielle Sinead Potter, Thelma Mashaka, Richard M Stone, Daniel J DeAngelo, Anthony Letai, R Coleman Lindsley, Robert J Soiffer, Joseph H Antin
Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. Blood advances (2021)
Eytan M Stein, Daniel J DeAngelo, Jörg Chromik, Manik Chatterjee, Sebastian Bauer, Chia-Chi Lin, Cristina Suarez, Filip Yves Francine De Vos, Neeltje Steeghs, Philippe Alexandre Cassier, David Tai, Jean-Jacques Kiladjian, Noboru Yamamoto, Rogier Mous, Jordi Esteve, Hironobu Minami, Stéphane Ferretti, Nelson Guerreiro, Christophe Meille, Rajkumar Radhakrishnan, Bernard Pereira, Luisa Mariconti, Ensar Halilovic, Claire Fabre, Cecilia Carpio
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Yannis K Valtis, Kristen E Stevenson, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Giacomo Gotti, Andrew M Brunner, Mary Nauffal, Daniel J DeAngelo, Marlise R Luskin
Orthopedic Toxicities Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials. Blood advances (2021)
Hagop M Kantarjian, Wendy Stock, Ryan D Cassaday, Daniel J DeAngelo, Elias Jabbour, Susan M O'Brien, Matthias Stelljes, Tao Wang, M Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, A Douglas Laird, Anjali S Advani
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Christopher R Reilly, Mikko Myllymäki, Robert A Redd, Shilpa Padmanaban, Druha Karunakaran, Valerie Tesmer, Frederick D Tsai, Christopher J Gibson, Huma Q Rana, Liang Zhong, Wael Saber, Stephen R Spellman, Zhen-Huan Hu, Esther H Orr, Maxine M Chen, Immaculata De Vivo, Daniel J DeAngelo, Corey Cutler, Joseph H Antin, Donna Neuberg, Judy E Garber, Jayakrishnan Nandakumar, Suneet Agarwal, R Coleman Lindsley
The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood 138 (10) (2021)
Andrew Hantel, Marlise R Luskin, Jacqueline S Garcia, Wendy Stock, Daniel J DeAngelo, Gregory A Abel
Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood advances 5 (21) (2021)
Daniel J DeAngelo, Brian A Jonas, Jane L Liesveld, Dale L Bixby, Anjali S Advani, Paula Marlton, John L Magnani, Helen M Thackray, Eric J Feldman, Michael E O'Dwyer, Pamela S Becker
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood (2021)
Jason Gotlib, Andreas Reiter, Deepti H Radia, Michael W Deininger, Tracy I George, Jens Panse, Alessandro M Vannucchi, Uwe Platzbecker, Iván Alvarez-Twose, Andrzej Mital, Olivier Hermine, Ingunn Dybedal, Elizabeth O Hexner, Lisa K Hicks, Lambert Span, Ruben Mesa, Prithviraj Bose, Kristen M Pettit, Mark L Heaney, Stephen T Oh, Jayita Sen, Hui-Min Lin, Brenton G Mar, Daniel J DeAngelo
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nature medicine (2021)
Praveen Anand, Amy Guillaumet-Adkins, Valeriya Dimitrova, Huiyoung Yun, Yotam Drier, Noori Sotudeh, Anna J Rogers, Madhu M Ouseph, Monica Nair, Sayalee Potdar, Randi Isenhart, Jake A Kloeber, Tushara Vijaykumar, Leili Niu, Tiffaney Vincent, Guangwu Guo, Julia Frede, Marian H Harris, Andrew E Place, Lewis B Silverman, David Trent Teachey, Andrew A Lane, Daniel J DeAngelo, Jon C Aster, Bradley E Bernstein, Jens G Lohr, Birgit Knoechel
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood 137 (18) (2021)
Sarah Beth Mueller, Paola Dal Cin, Long Phi Le, Dora Dias-Santagata, Jochen K Lennerz, Anthony John Iafrate, Hetal D Marble, Andrew M Brunner, Matthew Weinstock, Marlise R Luskin, Daniel J DeAngelo, Richard M Stone, Valentina Nardi
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood advances (2021)
Daniel J DeAngelo, Deepti H Radia, Tracy I George, William A Robinson, Albert T Quiery, Mark W Drummond, Prithviraj Bose, Elizabeth O Hexner, Elliott F Winton, Hans-Peter Horny, Meera Tugnait, Oleg Schmidt-Kittler, Erica K Evans, Hui-Min Lin, Brenton G Mar, Srdan Verstovsek, Michael W Deininger, Jason Gotlib
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature medicine (2021)
Daniel J DeAngelo, Anjali S Advani, David I Marks, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Elias Jabbour, Akil Merchant, Tao Wang, Erik Vandendries, Alexander Neuhof, Hagop Kantarjian, Susan O'Brien
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood cancer journal 10 (8) (2020)
Gregory A Abel, Haesook T Kim, Andrew Hantel, David P Steensma, Richard Stone, Anand Habib, Vincent T Ho, Martha Wadleigh, Areej El-Jawahri, Edwin P Alyea, Daniel J DeAngelo, John Koreth, Joseph H Antin, Robert J Soiffer, Corey S Cutler
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia 35 (4) (2020)

Daniel J DeAngelo.css-eqlu8i{font-size:small;padding-left:4px;} (Daniel DeAngelo)

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel J DeAngelo (Daniel DeAngelo)